Kwangdong Pharmaceutical

광동제약 · 009290

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$236.4M (₩326.2B)

Overview

Kwangdong Pharmaceutical makes medicines and health-care products supplied to consumers and patients in South Korea.

The company is listed on KOSPI, South Korea's main stock exchange, and operates across both prescription pharmaceuticals and consumer health products. Because the filing text provided does not detail specific product lines or structural facts, the business is best described at the general level of a diversified Korean pharmaceutical company.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$1.2B

▲ +1.2% YoY

Operating profit · FY2025

US$22.5M

▲ +3.2% YoY

Net income · FY2025

US$15.5M

▼ −49.0% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$1.1B(₩1.5T)	US$1.2B(₩1.6T)	US$1.2B(₩1.7T)
Operating profit	US$30.5M(₩42.1B)	US$21.8M(₩30.1B)	US$22.5M(₩31B)
Net income	US$28.5M(₩39.4B)	US$30.3M(₩41.8B)	US$15.5M(₩21.3B)

Revenue

FY2023US$1.1B
FY2024US$1.2B
FY2025US$1.2B

Operating profit

FY2023US$30.5M
FY2024US$21.8M
FY2025US$22.5M

Net income

FY2023US$28.5M
FY2024US$30.3M
FY2025US$15.5M

Key ratios (FY2025)

ROE

3.0%

Debt/Eq

85.5%

Op. margin

1.9%

Net margin

1.3%

Rev. YoY

▲ +1.2%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?